In addition, preclinical evidence has shown that ibrutinib effectively ameliorates disease symptoms in patient samples or animal models of SLE, MS, systemic sclerosis (SSc), neuropathy with anti-myelin-associated glycoprotein (MAG), type 2 diabetes (T2D) and obesity (118, 119, 121–125). The gene discussed is MAG; the disease is obesity due to melanocortin 4 receptor deficiency.